These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9179629)

  • 1. A review of the psychomotor effects of paroxetine.
    Hawley CJ; McPhee S; Quick SJ; Smith VR
    Int Clin Psychopharmacol; 1997 Jan; 12(1):13-8. PubMed ID: 9179629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
    Kamijima K; Aoki M
    Expert Rev Neurother; 2006 Jul; 6(7):945-56. PubMed ID: 16831110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial.
    Rapaport MH; Lydiard RB; Pitts CD; Schaefer D; Bartolic EI; Iyengar M; Carfagno M; Lipschitz A
    J Clin Psychiatry; 2009 Jan; 70(1):46-57. PubMed ID: 19026248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withdrawal hypomania associated with paroxetine.
    Landry P; Roy L
    J Clin Psychopharmacol; 1997 Feb; 17(1):60-1. PubMed ID: 9004064
    [No Abstract]   [Full Text] [Related]  

  • 5. Serotonin syndrome after a massive overdose of controlled-release paroxetine.
    Muzyk AJ; Jakel RJ; Preud'homme X
    Psychosomatics; 2010; 51(5):437-42. PubMed ID: 20833944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delirium and multiple electrolyte abnormalities associated with high dose paroxetine exposure.
    Chuang YF; Chiu YL; Hwang TJ; Chu TS
    Psychiatry Clin Neurosci; 2006 Oct; 60(5):642-3. PubMed ID: 16958954
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and tolerability of controlled-release paroxetine.
    Golden RN
    Psychopharmacol Bull; 2003; 37 Suppl 1():176-86. PubMed ID: 14566210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study.
    Stein DJ; Andersen EW; Tonnoir B; Fineberg N
    Curr Med Res Opin; 2007 Apr; 23(4):701-11. PubMed ID: 17407626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR.
    DeVane CL
    Psychopharmacol Bull; 2003; 37 Suppl 1():29-41. PubMed ID: 14566199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower gastrointestinal bleeding and paroxetine use: two case reports.
    Blasco-Fontecilla H; de Leon J
    Psychosomatics; 2012; 53(2):184-7. PubMed ID: 22424167
    [No Abstract]   [Full Text] [Related]  

  • 12. Elevation of nortriptyline plasma levels after cotreatment with paroxetine and thioridazine.
    Ghaemi SN; Kirkwood CK
    J Clin Psychopharmacol; 1998 Aug; 18(4):342-3. PubMed ID: 9690702
    [No Abstract]   [Full Text] [Related]  

  • 13. Granuloma annulare photoinduced by paroxetine.
    Álvarez-Pérez A; Gómez-Bernal S; Gutiérrez-González E; Rodríguez-Granados MT; Toribio J
    Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):47-9. PubMed ID: 22212003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response.
    Benkert O; Szegedi A; Wetzel H; Staab HJ; Meister W; Philipp M
    Acta Psychiatr Scand; 1997 Apr; 95(4):288-96. PubMed ID: 9150822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use.
    Abraham JT; Brown R; Meltzer HY
    Biol Psychiatry; 1997 Jul; 42(2):144-6. PubMed ID: 9209732
    [No Abstract]   [Full Text] [Related]  

  • 16. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group.
    Baldwin D; Bobes J; Stein DJ; Scharwächter I; Faure M
    Br J Psychiatry; 1999 Aug; 175():120-6. PubMed ID: 10627793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid cycling triggered by pindolol augmentation of paroxetine, but not with desipramine.
    Kraus RP
    Depression; 1996; 4(2):92-4. PubMed ID: 9160648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
    Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
    Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant-like effects of paroxetine are produced by lower doses than those which produce nausea.
    Tuerke KJ; Leri F; Parker LA
    Pharmacol Biochem Behav; 2009 Aug; 93(2):190-5. PubMed ID: 19477193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy.
    Lauritzen L; Odgaard K; Clemmesen L; Lunde M; Ohrström J; Black C; Bech P
    Acta Psychiatr Scand; 1996 Oct; 94(4):241-51. PubMed ID: 8911559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.